<p>在當今快速變化且競爭激烈的商業世界中，投資者和行業愛好者仔細評估公司至關重要。本文將對製藥行業的 <strong>輝瑞（NYSE: PFE）</strong> 進行全面的行業比較，評估其與主要競爭對手的表現。通過分析重要的財務指標、市場地位和增長前景，我們旨在為投資者提供有價值的見解，並揭示公司在行業中的表現。</p>
<h3>輝瑞背景</h3>
<p>輝瑞是全球最大的製藥公司之一，年銷售額約為 600 億美元。雖然輝瑞歷史上銷售多種類型的醫療產品和化學品，但目前處方藥和疫苗佔據了大部分銷售額。主要暢銷產品包括肺炎球菌疫苗 Prevnar 13 和心臟病藥物 Vyndaqel 和 Eliquis。輝瑞在全球範圍內銷售這些產品，國際銷售佔總銷售額的 40%。在國際銷售中，新興市場是一個主要貢獻者。</p>
<table>
<thead>
<tr>
<th><strong>公司</strong></th>
<th><strong>市盈率</strong></th>
<th><strong>市淨率</strong></th>
<th><strong>市銷率</strong></th>
<th><strong>股本回報率</strong></th>
<th><strong>息税折舊攤銷前利潤（十億美元）</strong></th>
<th><strong>毛利潤（十億美元）</strong></th>
<th><strong>收入增長</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>輝瑞公司</td>
<td>14.56</td>
<td>1.53</td>
<td>2.28</td>
<td>3.9%</td>
<td>$5.65</td>
<td>$12.48</td>
<td>-5.91%</td>
</tr>
<tr>
<td>禮來公司</td>
<td>51.04</td>
<td>39.19</td>
<td>15.79</td>
<td>26.54%</td>
<td>$7.88</td>
<td>$14.59</td>
<td>53.87%</td>
</tr>
<tr>
<td>強生公司</td>
<td>20.32</td>
<td>6.39</td>
<td>5.54</td>
<td>6.53%</td>
<td>$9.52</td>
<td>$16.69</td>
<td>6.77%</td>
</tr>
<tr>
<td>阿斯利康公司</td>
<td>29.85</td>
<td>6.07</td>
<td>4.83</td>
<td>5.59%</td>
<td>$5.23</td>
<td>$12.39</td>
<td>11.99%</td>
</tr>
<tr>
<td>諾華公司</td>
<td>18.47</td>
<td>5.84</td>
<td>4.73</td>
<td>9.1%</td>
<td>$5.84</td>
<td>$10.82</td>
<td>9.0%</td>
</tr>
<tr>
<td>默克公司</td>
<td>13.12</td>
<td>4.75</td>
<td>3.89</td>
<td>11.47%</td>
<td>$8.23</td>
<td>$13.42</td>
<td>3.72%</td>
</tr>
<tr>
<td>諾和諾德公司</td>
<td>13.01</td>
<td>7.94</td>
<td>4.28</td>
<td>11.84%</td>
<td>$31.44</td>
<td>$57.07</td>
<td>5.14%</td>
</tr>
<tr>
<td>賽諾菲公司</td>
<td>15.63</td>
<td>1.36</td>
<td>2.19</td>
<td>3.91%</td>
<td>$4.2</td>
<td>$9.76</td>
<td>1.49%</td>
</tr>
<tr>
<td>布里斯托爾 - 邁爾斯斯奎布公司</td>
<td>18.03</td>
<td>5.88</td>
<td>2.27</td>
<td>12.23%</td>
<td>$4.61</td>
<td>$8.79</td>
<td>2.77%</td>
</tr>
<tr>
<td>GSK 公司</td>
<td>13.69</td>
<td>4.55</td>
<td>2.34</td>
<td>13.01%</td>
<td>$3.36</td>
<td>$6.29</td>
<td>6.68%</td>
</tr>
<tr>
<td>Zoetis 公司</td>
<td>20.58</td>
<td>9.98</td>
<td>5.81</td>
<td>13.9%</td>
<td>$1.07</td>
<td>$1.72</td>
<td>0.5%</td>
</tr>
<tr>
<td>武田藥品工業公司</td>
<td>218.12</td>
<td>0.99</td>
<td>1.63</td>
<td>-0.17%</td>
<td>$316.47</td>
<td>$732.74</td>
<td>-5.38%</td>
</tr>
<tr>
<td>Teva 製藥工業公司</td>
<td>49.28</td>
<td>4.76</td>
<td>2.07</td>
<td>6.15%</td>
<td>$1.1</td>
<td>$2.3</td>
<td>3.42%</td>
</tr>
<tr>
<td>Dr Reddy's 實驗室公司</td>
<td>17.99</td>
<td>2.94</td>
<td>3.08</td>
<td>4.06%</td>
<td>$24.31</td>
<td>$48.14</td>
<td>9.84%</td>
</tr>
<tr>
<td>Elanco 動物健康公司</td>
<td>315.43</td>
<td>1.63</td>
<td>2.41</td>
<td>-0.5%</td>
<td>$0.18</td>
<td>$0.61</td>
<td>10.39%</td>
</tr>
<tr>
<td>Corcept 治療公司</td>
<td>94.57</td>
<td>13.70</td>
<td>13.30</td>
<td>3.05%</td>
<td>$0.01</td>
<td>$0.2</td>
<td>13.75%</td>
</tr>
<tr>
<td><strong>平均</strong></td>
<td><strong>60.61</strong></td>
<td><strong>7.73</strong></td>
<td><strong>4.94</strong></td>
<td><strong>8.45%</strong></td>
<td><strong>$28.23</strong></td>
<td><strong>$62.37</strong></td>
<td><strong>8.93%</strong></td>
</tr>
</tbody>
</table>
<p>通過對輝瑞進行深入分析，我們可以識別出以下趨勢：</p>
<ul>
<li>該股票的市盈率為 14.56，低於行業平均水平 0.24 倍，暗示市場參與者可能認為其具有潛在價值。</li>
</ul>
<ul>
<li>考慮到市淨率為 1.53，遠低於行業平均水平 0.2 倍，該股票可能在其賬面價值基礎上被低估。</li>
</ul>
<ul>
<li>該公司的市銷率相對較低，為 2.28，只有行業平均水平的 0.46 倍，可能被認為在銷售表現上被低估。</li>
</ul>
<ul>
<li>公司的股本回報率（ROE）為 3.9%，低於行業平均水平 4.55%。這表明在利用股本產生利潤方面可能存在效率低下，可能與多種因素有關。</li>
</ul>
<ul>
<li>公司的息税折舊攤銷前利潤（EBITDA）為 56.5 億美元，低於行業平均水平 0.2 倍。這可能表明盈利能力較低或面臨財務挑戰。</li>
</ul>
<ul>
<li>公司的毛利潤為 124.8 億美元，低於行業平均水平 0.2 倍。這可能表明在扣除生產成本後收入較低。</li>
</ul>
<ul>
<li>收入增長為-5.91%，遠低於行業平均水平 8.93%，公司在銷售擴張方面正經歷顯著放緩。</li>
</ul>
<h3>債務與股本比率</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766070063_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="債務與股本" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766070063_0.png"/></p>
<p>債務與股本比率（D/E）是一個衡量公司相對於其淨資產價值所承擔債務水平的指標。</p>
<p>在行業比較中考慮債務與股本比率，可以簡潔地評估公司的財務健康狀況和風險特徵，幫助做出明智的決策。</p>
<p>通過分析輝瑞與其在債務與股本比率方面的前四大同行的關係，可以得出以下見解：</p>
<ul>
<li>輝瑞在該行業的前四大同行中展現出更強的財務狀況。</li>
</ul>
<ul>
<li>公司的債務與股本比率為 0.66，低於同行，表明公司對債務融資的依賴較小，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極信號。</li>
</ul>
<h3>關鍵要點</h3>
<p>對於輝瑞而言，其市盈率、市淨率和市銷率均低於製藥行業的同行，表明可能被低估。然而，輝瑞的低 ROE 表明其盈利能力低於行業同行。此外，低 EBITDA、毛利潤和收入增長進一步突顯了在與競爭對手相比時，產生利潤和收入增長的潛在挑戰。</p>
<p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>

輝瑞

<p>本文對輝瑞在製藥行業中的競爭對手進行了評估，分析了市盈率（PE）、市淨率（PB）、市銷率（PS）、股本回報率（ROE）、息税折舊攤銷前利潤（EBITDA）和收入增長等財務指標。輝瑞顯示出潛在的低估，但在盈利能力和收入增長方面面臨挑戰。與主要競爭對手相比，輝瑞的財務狀況更強，債務與股本比率較低，表明其對債務融資的依賴程度較低。該分析為投資者提供了有關輝瑞市場地位和財務健康狀況的見解</p>

<p>In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating <strong>Pfizer (NYSE: PFE)</strong> against its key competitors in the Pharmaceuticals industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.</p>
<div class="lb-trans"><p>在當今快速變化且競爭激烈的商業世界中，投資者和行業愛好者仔細評估公司至關重要。本文將對製藥行業的 <strong>輝瑞（NYSE: PFE）</strong> 進行全面的行業比較，評估其與主要競爭對手的表現。通過分析重要的財務指標、市場地位和增長前景，我們旨在為投資者提供有價值的見解，並揭示公司在行業中的表現。</p>
</div><h3>Pfizer Background</h3>
<div class="lb-trans"><h3>輝瑞背景</h3>
</div><p>Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.</p>
<div class="lb-trans"><p>輝瑞是全球最大的製藥公司之一，年銷售額約為 600 億美元。雖然輝瑞歷史上銷售多種類型的醫療產品和化學品，但目前處方藥和疫苗佔據了大部分銷售額。主要暢銷產品包括肺炎球菌疫苗 Prevnar 13 和心臟病藥物 Vyndaqel 和 Eliquis。輝瑞在全球範圍內銷售這些產品，國際銷售佔總銷售額的 40%。在國際銷售中，新興市場是一個主要貢獻者。</p>
</div><table>
<thead>
<tr>
<th><strong>Company</strong></th>
<th><strong>P/E</strong></th>
<th><strong>P/B</strong></th>
<th><strong>P/S</strong></th>
<th><strong>ROE</strong></th>
<th><strong>EBITDA (in billions)</strong></th>
<th><strong>Gross Profit (in billions)</strong></th>
<th><strong>Revenue Growth</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Inc</td>
<td>14.56</td>
<td>1.53</td>
<td>2.28</td>
<td>3.9%</td>
<td>$5.65</td>
<td>$12.48</td>
<td>-5.91%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>51.04</td>
<td>39.19</td>
<td>15.79</td>
<td>26.54%</td>
<td>$7.88</td>
<td>$14.59</td>
<td>53.87%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>20.32</td>
<td>6.39</td>
<td>5.54</td>
<td>6.53%</td>
<td>$9.52</td>
<td>$16.69</td>
<td>6.77%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>29.85</td>
<td>6.07</td>
<td>4.83</td>
<td>5.59%</td>
<td>$5.23</td>
<td>$12.39</td>
<td>11.99%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>18.47</td>
<td>5.84</td>
<td>4.73</td>
<td>9.1%</td>
<td>$5.84</td>
<td>$10.82</td>
<td>9.0%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc</td>
<td>13.12</td>
<td>4.75</td>
<td>3.89</td>
<td>11.47%</td>
<td>$8.23</td>
<td>$13.42</td>
<td>3.72%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>13.01</td>
<td>7.94</td>
<td>4.28</td>
<td>11.84%</td>
<td>$31.44</td>
<td>$57.07</td>
<td>5.14%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>15.63</td>
<td>1.36</td>
<td>2.19</td>
<td>3.91%</td>
<td>$4.2</td>
<td>$9.76</td>
<td>1.49%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co</td>
<td>18.03</td>
<td>5.88</td>
<td>2.27</td>
<td>12.23%</td>
<td>$4.61</td>
<td>$8.79</td>
<td>2.77%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>13.69</td>
<td>4.55</td>
<td>2.34</td>
<td>13.01%</td>
<td>$3.36</td>
<td>$6.29</td>
<td>6.68%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>20.58</td>
<td>9.98</td>
<td>5.81</td>
<td>13.9%</td>
<td>$1.07</td>
<td>$1.72</td>
<td>0.5%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>218.12</td>
<td>0.99</td>
<td>1.63</td>
<td>-0.17%</td>
<td>$316.47</td>
<td>$732.74</td>
<td>-5.38%</td>
</tr>
<tr>
<td>Teva Pharmaceutical Industries Ltd</td>
<td>49.28</td>
<td>4.76</td>
<td>2.07</td>
<td>6.15%</td>
<td>$1.1</td>
<td>$2.3</td>
<td>3.42%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>17.99</td>
<td>2.94</td>
<td>3.08</td>
<td>4.06%</td>
<td>$24.31</td>
<td>$48.14</td>
<td>9.84%</td>
</tr>
<tr>
<td>Elanco Animal Health Inc</td>
<td>315.43</td>
<td>1.63</td>
<td>2.41</td>
<td>-0.5%</td>
<td>$0.18</td>
<td>$0.61</td>
<td>10.39%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>94.57</td>
<td>13.70</td>
<td>13.30</td>
<td>3.05%</td>
<td>$0.01</td>
<td>$0.2</td>
<td>13.75%</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>60.61</strong></td>
<td><strong>7.73</strong></td>
<td><strong>4.94</strong></td>
<td><strong>8.45%</strong></td>
<td><strong>$28.23</strong></td>
<td><strong>$62.37</strong></td>
<td><strong>8.93%</strong></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>公司</strong></th>
<th><strong>市盈率</strong></th>
<th><strong>市淨率</strong></th>
<th><strong>市銷率</strong></th>
<th><strong>股本回報率</strong></th>
<th><strong>息税折舊攤銷前利潤（十億美元）</strong></th>
<th><strong>毛利潤（十億美元）</strong></th>
<th><strong>收入增長</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>輝瑞公司</td>
<td>14.56</td>
<td>1.53</td>
<td>2.28</td>
<td>3.9%</td>
<td>$5.65</td>
<td>$12.48</td>
<td>-5.91%</td>
</tr>
<tr>
<td>禮來公司</td>
<td>51.04</td>
<td>39.19</td>
<td>15.79</td>
<td>26.54%</td>
<td>$7.88</td>
<td>$14.59</td>
<td>53.87%</td>
</tr>
<tr>
<td>強生公司</td>
<td>20.32</td>
<td>6.39</td>
<td>5.54</td>
<td>6.53%</td>
<td>$9.52</td>
<td>$16.69</td>
<td>6.77%</td>
</tr>
<tr>
<td>阿斯利康公司</td>
<td>29.85</td>
<td>6.07</td>
<td>4.83</td>
<td>5.59%</td>
<td>$5.23</td>
<td>$12.39</td>
<td>11.99%</td>
</tr>
<tr>
<td>諾華公司</td>
<td>18.47</td>
<td>5.84</td>
<td>4.73</td>
<td>9.1%</td>
<td>$5.84</td>
<td>$10.82</td>
<td>9.0%</td>
</tr>
<tr>
<td>默克公司</td>
<td>13.12</td>
<td>4.75</td>
<td>3.89</td>
<td>11.47%</td>
<td>$8.23</td>
<td>$13.42</td>
<td>3.72%</td>
</tr>
<tr>
<td>諾和諾德公司</td>
<td>13.01</td>
<td>7.94</td>
<td>4.28</td>
<td>11.84%</td>
<td>$31.44</td>
<td>$57.07</td>
<td>5.14%</td>
</tr>
<tr>
<td>賽諾菲公司</td>
<td>15.63</td>
<td>1.36</td>
<td>2.19</td>
<td>3.91%</td>
<td>$4.2</td>
<td>$9.76</td>
<td>1.49%</td>
</tr>
<tr>
<td>布里斯托爾 - 邁爾斯斯奎布公司</td>
<td>18.03</td>
<td>5.88</td>
<td>2.27</td>
<td>12.23%</td>
<td>$4.61</td>
<td>$8.79</td>
<td>2.77%</td>
</tr>
<tr>
<td>GSK 公司</td>
<td>13.69</td>
<td>4.55</td>
<td>2.34</td>
<td>13.01%</td>
<td>$3.36</td>
<td>$6.29</td>
<td>6.68%</td>
</tr>
<tr>
<td>Zoetis 公司</td>
<td>20.58</td>
<td>9.98</td>
<td>5.81</td>
<td>13.9%</td>
<td>$1.07</td>
<td>$1.72</td>
<td>0.5%</td>
</tr>
<tr>
<td>武田藥品工業公司</td>
<td>218.12</td>
<td>0.99</td>
<td>1.63</td>
<td>-0.17%</td>
<td>$316.47</td>
<td>$732.74</td>
<td>-5.38%</td>
</tr>
<tr>
<td>Teva 製藥工業公司</td>
<td>49.28</td>
<td>4.76</td>
<td>2.07</td>
<td>6.15%</td>
<td>$1.1</td>
<td>$2.3</td>
<td>3.42%</td>
</tr>
<tr>
<td>Dr Reddy's 實驗室公司</td>
<td>17.99</td>
<td>2.94</td>
<td>3.08</td>
<td>4.06%</td>
<td>$24.31</td>
<td>$48.14</td>
<td>9.84%</td>
</tr>
<tr>
<td>Elanco 動物健康公司</td>
<td>315.43</td>
<td>1.63</td>
<td>2.41</td>
<td>-0.5%</td>
<td>$0.18</td>
<td>$0.61</td>
<td>10.39%</td>
</tr>
<tr>
<td>Corcept 治療公司</td>
<td>94.57</td>
<td>13.70</td>
<td>13.30</td>
<td>3.05%</td>
<td>$0.01</td>
<td>$0.2</td>
<td>13.75%</td>
</tr>
<tr>
<td><strong>平均</strong></td>
<td><strong>60.61</strong></td>
<td><strong>7.73</strong></td>
<td><strong>4.94</strong></td>
<td><strong>8.45%</strong></td>
<td><strong>$28.23</strong></td>
<td><strong>$62.37</strong></td>
<td><strong>8.93%</strong></td>
</tr>
</tbody>
</table>
</div><p>By conducting an in-depth analysis of Pfizer, we can identify the following trends:</p>
<div class="lb-trans"><p>通過對輝瑞進行深入分析，我們可以識別出以下趨勢：</p>
</div><ul>
<li>The stock's Price to Earnings ratio of 14.56 is lower than the industry average by 0.24x, suggesting potential value in the eyes of market participants.</li>
</ul>
<div class="lb-trans"><ul>
<li>該股票的市盈率為 14.56，低於行業平均水平 0.24 倍，暗示市場參與者可能認為其具有潛在價值。</li>
</ul>
</div><ul>
<li>Considering a Price to Book ratio of 1.53, which is well below the industry average by 0.2x, the stock may be undervalued based on its book value compared to its peers.</li>
</ul>
<div class="lb-trans"><ul>
<li>考慮到市淨率為 1.53，遠低於行業平均水平 0.2 倍，該股票可能在其賬面價值基礎上被低估。</li>
</ul>
</div><ul>
<li>With a relatively low Price to Sales ratio of 2.28, which is 0.46x the industry average, the stock might be considered undervalued based on sales performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>該公司的市銷率相對較低，為 2.28，只有行業平均水平的 0.46 倍，可能被認為在銷售表現上被低估。</li>
</ul>
</div><ul>
<li>The company has a lower Return on Equity (ROE) of 3.9%, which is 4.55% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.</li>
</ul>
<div class="lb-trans"><ul>
<li>公司的股本回報率（ROE）為 3.9%，低於行業平均水平 4.55%。這表明在利用股本產生利潤方面可能存在效率低下，可能與多種因素有關。</li>
</ul>
</div><ul>
<li>The company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.65 Billion, which is 0.2x below the industry average. This potentially indicates lower profitability or financial challenges.</li>
</ul>
<div class="lb-trans"><ul>
<li>公司的息税折舊攤銷前利潤（EBITDA）為 56.5 億美元，低於行業平均水平 0.2 倍。這可能表明盈利能力較低或面臨財務挑戰。</li>
</ul>
</div><ul>
<li>The company has lower gross profit of $12.48 Billion, which indicates 0.2x below the industry average. This potentially indicates lower revenue after accounting for production costs.</li>
</ul>
<div class="lb-trans"><ul>
<li>公司的毛利潤為 124.8 億美元，低於行業平均水平 0.2 倍。這可能表明在扣除生產成本後收入較低。</li>
</ul>
</div><ul>
<li>With a revenue growth of -5.91%, which is much lower than the industry average of 8.93%, the company is experiencing a notable slowdown in sales expansion.</li>
</ul>
<div class="lb-trans"><ul>
<li>收入增長為-5.91%，遠低於行業平均水平 8.93%，公司在銷售擴張方面正經歷顯著放緩。</li>
</ul>
</div><h3>Debt To Equity Ratio</h3>
<div class="lb-trans"><h3>債務與股本比率</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766070063_0.png" alt="debt to equity" original-src="https://www.benzinga.com/files/images/story/2025/1766070063_0.png"/></p>
<p>The debt-to-equity (D/E) ratio is a measure that indicates the level of debt a company has taken on relative to the value of its assets net of liabilities.</p>
<div class="lb-trans"><p>債務與股本比率（D/E）是一個衡量公司相對於其淨資產價值所承擔債務水平的指標。</p>
</div><p>Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.</p>
<div class="lb-trans"><p>在行業比較中考慮債務與股本比率，可以簡潔地評估公司的財務健康狀況和風險特徵，幫助做出明智的決策。</p>
</div><p>By analyzing Pfizer in relation to its top 4 peers based on the Debt-to-Equity ratio, the following insights can be derived:</p>
<div class="lb-trans"><p>通過分析輝瑞與其在債務與股本比率方面的前四大同行的關係，可以得出以下見解：</p>
</div><ul>
<li>Pfizer demonstrates a stronger financial position compared to its top 4 peers in the sector.</li>
</ul>
<div class="lb-trans"><ul>
<li>輝瑞在該行業的前四大同行中展現出更強的財務狀況。</li>
</ul>
</div><ul>
<li>With a lower debt-to-equity ratio of 0.66, the company relies less on debt financing and maintains a healthier balance between debt and equity, which can be viewed positively by investors.</li>
</ul>
<div class="lb-trans"><ul>
<li>公司的債務與股本比率為 0.66，低於同行，表明公司對債務融資的依賴較小，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極信號。</li>
</ul>
</div><h3>Key Takeaways</h3>
<div class="lb-trans"><h3>關鍵要點</h3>
</div><p>For Pfizer, the PE, PB, and PS ratios are all low compared to its peers in the Pharmaceuticals industry, indicating potential undervaluation. However, Pfizer's low ROE suggests lower profitability compared to industry peers. Additionally, the low EBITDA, gross profit, and revenue growth further highlight potential challenges in generating profits and revenue growth compared to its competitors.</p>
<div class="lb-trans"><p>對於輝瑞而言，其市盈率、市淨率和市銷率均低於製藥行業的同行，表明可能被低估。然而，輝瑞的低 ROE 表明其盈利能力低於行業同行。此外，低 EBITDA、毛利潤和收入增長進一步突顯了在與競爭對手相比時，產生利潤和收入增長的潛在挑戰。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>
</div>

Industry Comparison: Evaluating Pfizer Against Competitors In Pharmaceuticals Industry

- 輝瑞在製藥行業的市盈率、淨資產收益率等指標低於行業平均水平。  
- 輝瑞的收入增長為負，表明銷售擴展放緩，面臨盈利挑戰。  
- 相對較低的負債比率顯示輝瑞的財務狀況較同業競爭者更為穩健。

行業比較：評估輝瑞在製藥行業中與競爭對手的表現